Sugi Predict

Sugi Predict / Targets / NCK1

NCK1

SH2/SH3 adapter protein NCK1 · P16333 · NCK1 on Sugi Atlas →

840 patent compounds predicted against NCK1, 620 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7048523 SCHEMBL7048523 1.00 1/20
SCHEMBL7049649 SCHEMBL7049649 0.73 1/20
Morpholine Morpholine (SCHEMBL27949689) 0.68 1/20
SCHEMBL1133953 SCHEMBL1133953 0.64 1/20
SCHEMBL161703 SCHEMBL161703 0.63 1/20
SCHEMBL3412309 SCHEMBL3412309 0.63 1/20
SCHEMBL23247265 SCHEMBL23247265 0.63 1/20
SCHEMBL29444268 SCHEMBL29444268 0.63 1/20
SCHEMBL30503638 SCHEMBL30503638 0.63 1/20
SCHEMBL5478956 SCHEMBL5478956 0.62 1/20
SCHEMBL11702937 SCHEMBL11702937 0.61 1/20
SCHEMBL9755319 SCHEMBL9755319 0.61 1/20
SCHEMBL15344932 SCHEMBL15344932 0.60 1/20
SCHEMBL27960667 SCHEMBL27960667 0.60 1/20
SCHEMBL9312 SCHEMBL9312 0.59 1/20
SCHEMBL1598520 SCHEMBL1598520 0.59 1/20
SCHEMBL1724450 SCHEMBL1724450 0.59 1/20
SCHEMBL2130719 SCHEMBL2130719 0.59 1/20
SCHEMBL3455999 SCHEMBL3455999 0.59 1/20
SCHEMBL4468871 SCHEMBL4468871 0.59 1/20

Clinical trials — most relevant to NCK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCK1 binder may also engage these)

ProteinNameSimilarity
Q99M51 — 1.000 Q99M51 →
O43639 — 0.996 O43639 →
O55033 — 0.989 O55033 →
Q9R0C8 — 0.980 Q9R0C8 →
Q09014 — 0.970 Q09014 →
Q08DN7 — 0.970 Q08DN7 →
P52735 — 0.970 P52735 →
Q5XGP7 — 0.969 Q5XGP7 →
VAV1 Proto-oncogene vav 0.969 landscape →
Q9XYM0 — 0.968 Q9XYM0 →
Q5FVW6 — 0.968 Q5FVW6 →
Q9UKW4 — 0.968 Q9UKW4 →
HCK Tyrosine-protein kinase HCK 0.967 landscape →
P25911 — 0.967 P25911 →
Q6PG29 — 0.967 Q6PG29 →
P54100 — 0.967 P54100 →
O89100 — 0.966 O89100 →
Q07139 — 0.966 Q07139 →
P53666 — 0.965 P53666 →
Q1KKZ1 — 0.965 Q1KKZ1 →
Q6EWH2 — 0.965 Q6EWH2 →
P50545 — 0.964 P50545 →
Q5U597 — 0.964 Q5U597 →
A0JNJ1 — 0.964 A0JNJ1 →
Q8IPW2 — 0.963 Q8IPW2 →
A1Y2K1 — 0.963 A1Y2K1 →
P27447 — 0.963 P27447 →
Q9H8V3 — 0.962 Q9H8V3 →
P09760 — 0.962 P09760 →
Q60992 — 0.962 Q60992 →